TP53 and neoplasm: In two separate Phase 1 trials in conducted in adult and pediatric populations with TP53 mutant solid cancers (NCT01975116, NCT00914914), p28 was well-tolerated and demonstrated favorable pharmacokinetics, yet objective tumor responses were minimal [116,117].